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Dynamic weight-bearing assessment of
pain in knee osteoarthritis: construct
validity, responsiveness, and interpretability
in a research setting
Louise Klokker1* , Robin Christensen1, Eva E. Wæhrens1,2, Elisabeth Bandak1, Cecilie Bartholdy1,
Henning Bliddal1 and Marius Henriksen1,3
Abstract
Background: The Osteoarthritis Research Society International (OARSI) has suggested to asses pain after specific
activities consistently in clinical trials on knee OA. The Dynamic weight-bearing Assessment of Pain (DAP) assesses
pain during activity (30 s of performing repeated deep knee-bends from a standing position). The purpose of this
study is to evaluate the construct validity, responsiveness, and interpretability of the DAP for knee osteoarthritis (OA).
Methods: One-hundred participants with knee OA were tested twice each with the DAP, the Knee injury and
Osteoarthritis Outcome Score (KOOS), six-minute-walk-test (6MWT), and 6-min-walk-test with subsequent pain
rating (6MWTpain), and once with a transition questionnaire (TRANS-Q) for the patient-reported change in pain
after 12 weeks of exercise. Construct validity (baseline-scores) and responsiveness (change-scores) were estimated
by Spearman Correlation Coefficients. We hypothesized that no correlations would be excellent (<0.7) (divergent
validity), except for the 6MWTpain (convergent validity). The TRANS-Q was used for interpreting the DAP change-scores
in terms of responsiveness and Minimal Important Change (MIC).
Results: Divergent validity with the KOOS subscales (r = −0.31 to–0.45) and the 6MWT (r = −0.25) was supported.
Convergent validity with the 6MWTpain was not supported (r = 0.54). The DAP change-scores corresponded to
patient-reported change in pain (TRANS-Q), while correlations with change-scores on the other instruments were <0.35.
The MIC was 2.4 DAP points.
Conclusions: The DAP possesses divergent validity compared to other instruments for knee OA, supporting the potential
for this new way of assessing pain directly during activity. Importantly, the DAP change-scores correspond to
patient-reported changes in pain, showing responsiveness. A change of 2.4 or more can be interpreted as clinically
relevant. The DAP is a promising alternative to using ‘pain on walking’ as a clinical trial inclusion criterion/outcome.
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Background
The Dynamic weight-bearing Assessment of Pain (DAP)
for knee osteoarthritis (OA) is a simple test designed to
assess pain during performance of a specified activity in
patients with knee OA [1, 2]. It is a simple performance
test requiring repeated deep knee bends from a standing
position for 30 s, with subsequent rating of pain on a 0–10
numeric rating scale (NRS), where 0 indicates ‘no pain’
and 10 ‘worst pain imaginable.’ The DAP follows current
quality standards [3] to scientifically qualify a common
clinical practice: asking patients about their pain during
performance of a test. An elaborated description of the
test has been published previously [2].
Application of the DAP is in line with The Osteoarth-
ritis Research Society International (OARSI) suggestion
for clinical trials on knee OA; "Pain can be assessed after
specific activities (e.g., a walk test). If a pain assessment
occurs after an activity then the study team should en-
sure consistency throughout the trial with the type and
duration of activity as well as the timing of the pain as-
sessment after the activity" [4]. This consistency is best
obtained through a standardized test such as the DAP.
The DAP was developed based on input both from pa-
tients (with knee OA) and health care professionals.
Through focus groups, ‘weight-bearing deep knee bends’
was identified as a clinically important pain-provoking
activity that would translate to a feasible instrument for
‘pain during activity’ by adding patient reports of pain
[1]. The first version of the DAP had two scores: the
pain rating, and the knee bend count. A study on repro-
ducibility showed excellent properties of the pain score
in a population of patients with knee OA (Intra-rater
ICC = 0.93 [95 % CI 0.83 to 0.97], corresponding to a
Standard Error of Measurement (SEM = of 0.70, and a
Smallest Detectable Change (SDC) of 1.95; inter-rater
ICC 0.91, [95 % CI 0.78 to 0.96], SEM 0.86, SDC 2.39),
whereas the knee bend count did not reach acceptable
level [2]. Consequently, the knee bend score was omitted
and thus the second version of the DAP now consists of
a single pain score. Simultaneously we clarified the con-
struct assessed with the DAP to be ‘pain during activity’
instead of ‘the interaction between pain and function.’
The level of reliability is similar to that of pain ratings
subsequent to other performance tests in patients with
hip pain [5] and knee OA [6]. However, the validity, re-
sponsiveness, or interpretability of combined perform-
ance tests and pain ratings have not been evaluated.
We anticipate that the DAP assesses pain during per-
formance of a specific weight-bearing activity in pa-
tients with knee OA — a construct that adds a new
perspective to existing instruments. Our objectives
were to evaluate the construct (divergent and conver-
gent) validity, responsiveness, and interpretability of
the DAP instrument.
Methods
Participants
This study was nested within an assessor- and
participant-blinded randomized controlled trial compar-
ing corticosteroid injection with placebo given 2 weeks
prior to 12 weeks of supervised exercise in people with
knee OA [7]. Inclusion criteria for the trial were: age 40
and over, symptomatic and radiologically verified diag-
nosed knee OA, ‘pain while walking on a flat surface’ of
at least 4 on a 0–10 NRS, and a body mass index of 20
or more, but less than 35 kg/m2. Exclusion criteria in-
cluded use of intra-articular corticosteroids in the knee
or participation in physiotherapeutic exercise for knee
OA within the last 3 months, or severe concomitant dis-
eases. All participants in this study gave informed con-
sent before enrolling in the hosting trial. Each
participant received a copy of the consent.
Instrumentation
Dynamic weight-bearing Assessment of Pain (DAP)
The DAP [2] is a simple performance test with an inte-
grated pain score, designed to provide useful informa-
tion for monitoring treatment progress and evaluating
treatment effects in knee OA. The patient is asked to
perform as many standing knee-bends as possible within
30 s. For each knee bend, the knees should reach close
to 90° of flexion and full extension. This movement is
supervised by the rater. The test score is self-reported
pain intensity during knee bends on a 0–10 NRS re-
ported immediately after the 30 s of knee-bends as the
worst pain during the test. Thus, the pain intensity score
is an assessment of pain during performance of a spe-
cific weight-bearing activity. The DAP takes 1–2 min to
perform, including verbal instructions. Administering
the test does not require any equipment beside a stop-
watch/watch. The DAP was applied at baseline and at
the end-of-treatment visit.
Knee injury and Osteoarthritis Outcome Score (KOOS)
The KOOS [8] is a questionnaire for assessing patient-
reported symptoms. KOOS consists of 5 subscales
assessing different constructs: Symptoms (7 items),
Pain (9 items), Function in daily living (16 items),
Function in sports and recreation (5 items), and knee-
related Quality of Life (QoL) (4 items). Responses are
given using Likert boxes, and each question is assigned
a score from 0–4. A normalized score is calculated for
each subscale ranging from 0 (extreme symptoms) to
100 (no symptoms). Reliability of KOOS in an OA
population has been reported as acceptable [9]. The
KOOS questionnaire was applied at baseline and at the
end-of-treatment visit.
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Six-minute-walk-test (6MWT)
The 6MWT [10] is a walking test measuring the total
distance walked in 6 min. The distance is a surrogate
measure of functional capacity and cardiovascular func-
tion, originally used for patients with heart and lung dis-
eases. The 6MWT has shown acceptable test-retest
reliability and responsiveness in knee OA populations
[11, 12]; it was applied at baseline and at the end-of-
treatment visit.
Pain after 6MWT (6MWTpain)
Pain rating on a 0–10 NRS immediately after the
6MWT (6MWTpain) is not a standardized test. How-
ever, similar ratings of pain subsequent to a performance
test have been applied in other studies [5, 6]. The
6MWTpain was included to compare the DAP with this
other assessment of pain during a performance test. The
6MWTpain was applied at baseline and at the end-of-
treatment visit.
Transition questionnaire (TRANS-Q)
Transition ratings, or Global Perceived Effect scales, are
recommended as a core outcome measure in chronic
pain trials [13] and have been used as an external criter-
ion to determine responsiveness [14] or Minimal
Important Change (MIC) [3] of other measurement in-
struments. A transition questionnaire (TRANS-Q),
modified from Jaschke et al. [15], was used for asking
the participants about their experienced change in pain
after the intervention with the question: “Did your knee
pain change since you entered this project?” Response
options were: “It is unchanged,” “It is better,” and “It is
worse.” The ‘unchanged’ response is given a score of 0,
and no further questions are asked. The responses “It is
better” and “It is worse” bring up a seven-point scale,
with scores spanning from −7 (worst) to +7 (best), re-
spectively. For the purpose of this study, a clinically im-
portant change in pain was defined as a TRANS-Q score
of at least 2 (+2: a little better; −2: a little worse). No
change was defined as a TRANS-Q score of 0 (no
change) or +1/-1 (Almost the same, hardly any better/
worse at all). The transition questionnaire was imple-
mented in the hosting trial after the trial commenced
and therefore applicable to only a subset of the trial
participants. The transition questionnaire was adminis-
tered only at the end-of-treatment visit.
Kellgren & Lawrence
The Kellgren & Lawrence grading scale is used to assess
radiographic severity of knee OA based on radiographic
features; osteophytes, periarticular ossicles, narrowing of
joint cartilage, sclerotic tissue, altered shape of bone
ends. The scores are: 0 (no x-ray changes of OA), 1
(doubtful presence of OA), 2 (minimal presence of OA),
3 (moderate presence of OA), and 4 (severe presence of
OA) [16]. X-rays were taken at baseline and at the end-
of-treatment visit.
Ahlbäck classification
The Ahlbäck classification of radiographic knee OA of
the tibiofemoral joint also assesses radiographic severity
of OA and has five grades: 1 (joint space narrowing,
<3 mm), 2 (joint space obliteration), 3 (minor bone attri-
tion, 0-5 mm), 4 (moderate bone attrition, 5-10 mm), 5
(severe bone attrition, >10 mm) [17]. X-rays were taken
at baseline and at the end-of-treatment visit.
Statistical analysis
Analyses involving hypothesis testing for validity and re-
sponsiveness (i.e., the validity of a change score), and de-
termination of the Minimal Important Change (MIC) to
interpret change scores of the DAP were conducted ad-
hering to the COnsensus-based Standards for the selec-
tion of healthMeasurement INstruments (COSMIN)
methodology [3, 18].
For validation studies, a minimum sample size of 50 is
recommended, but larger samples are preferred [3].
There is currently no consensus on standards for deter-
mining sample size in MIC studies. The statistical ana-
lyses were performed using SAS statistical software
(version 9.3; SAS Institute Inc., Cary, NC, USA) and
follow the COSMIN standards [3]. As no gold standard
exists for the construct ‘pain during activity,’ validity and
responsiveness were evaluated through hypothesis
testing. The construct validity of the DAP was evaluated
by Spearman Correlation Coefficients with the other
outcome instruments using baseline scores. Likewise,
the responsiveness of the DAP was estimated by
Spearman Correlation Coefficients with the other out-
come instruments using change scores (baseline to
end-of-treatment). There is no consensus about the
magnitude of correlations required for acceptable
convergent or divergent validity [3, 19], indicating that
similar or different constructs, respectively, are assessed
by the two instruments being compared. As the DAP
was expected to assess a composite construct containing
aspects of the constructs assessed by the other instru-
ments, some correlation was expected. Thus, relatively
high correlation criteria were applied, for both validity
and responsiveness in this study; r >0.7 for convergence
and r <0.7 for divergence, based on the common appli-
cation of 0.7 as cutoff [20]. Correlations below 0.2 were
disregarded, as this is the critical point for a two-tailed
0.05 level of significance in an n = 100 sample (the
sample of the hosting trial) [7].
Both the DAP and the 6MWTpain were expected to
assess a construct of pain during activity (albeit two dif-
ferent activities). Thus, for both baseline and change
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scores, the DAP score correlations with the 6MWTpain
score were hypothesized to be convergent. The
6MWT reflects a construct of physical capacity/car-
diovascular function, whereas the subscales of the
KOOS assess symptoms, pain, function in daily living,
function in sports and recreation, and knee-related
quality of life. Thus, for both baseline and change
scores, the DAP score correlations with the 6MWT
and the KOOS subscales scores were hypothesized to
show divergence.
Responsiveness was further evaluated by patient-
reported change (TRANS-Q), hypothesizing that the
group that had experienced a change in pain would
have a greater mean change in DAP scores than the
group reporting no change in pain. Patient-reported
change of pain (TRANS-Q) were also used as an exter-
nal criterion to interpret the DAP change scores in
terms of the MIC, which we defined as the optimal cut-
off point on a Receiver Operating Characteristic (ROC)
curve (i.e., the value for which the sum of misclassifica-
tions ([1 – sensitivity] + [1 – specificity]) is smallest. [3]
The 95 % limit cutoff point is calculated as mean
change + 1.645 * SD change of the group of participants
who reported no change [3].
Results
As illustrated in Fig. 1, out of 100 participants included
in the hosting trial, 93 participants who were still in the
study by end of treatment were included in the present
analysis of validity and responsiveness; though for the
6MWTpain data for further 13 participants were miss-
ing. A convenience subsample of 41 participants from
the hosting trial was included in the analysis for respon-
siveness and interpretability using data from the
TRANS-Q. Baseline characteristics for the 93 partici-
pants included in the validity study are presented in
Table 1.
Validity
Our hypothesis about divergent validity was confirmed
with correlations <0.7 between baseline-scores of the
DAP and the 6MWT (r = −0.25), and the KOOS sub-
scales (r-values ranging from −0.31 to −0.45) (Table 2).
For baseline-scores of the DAP and the 6MWTpain, the
correlation (r = 0.54) did not reach the criterion for con-
vergence (r > 0.7), thus failing to support our hypothesis
about convergent validity.
Responsiveness
Our hypothesis about divergence was confirmed with
correlations <0.7 between change-scores of the DAP and
the 6MWT (r = −0.28) and the KOOS subscales (r-values
ranging from −0.10 to–0.31) (Table 2). However, out hy-
pothesis about convergence between the DAP and the
6MWTpain change-scores was not supported (r = 0.35).
Responsiveness of the DAP was supported, evaluated
by patient-reported change in pain; the participants
who had experienced a change (TRANS-Q rating of 2
or more) had higher DAP change scores (median
change: −2.0 points) than the group reporting no
change in pain (median change: −0.5 points; Table 3).
Interpretability
The MIC was established to be 1.5 DAP-points using
patient-reported change in pain (TRANS-Q of 2 or
more) as gold standard, corresponding to a sensitivity of
0.57 and a specificity of 1.00 (Table 4 and Fig. 2). The
95 % limit cutoff point is 2.3 (calculated as 0.0 +
1.65*1.4), corresponding to the upper confidence limit in
the group who experienced no change (Table 4). As the
previously established SMD is 1.94 for intra-rater test,
and 2.39 for inter-rater test [2], the MIC is changed to
2.4 DAP-points.
Discussion
These results suggest that the DAP has adequate proper-
ties for measuring a construct of pain during activity.
This construct is not covered by widely used instru-
ments for knee OA: the questionnaire KOOS and the
performance test 6MWT, as confirmed by divergent val-
idity. The correlation coefficient of 0.54 between the
DAP and the 6MWTpain suggests that the constructs
assessed with these two instruments are somewhat simi-
lar, although not fully convergent. The responsiveness of
the DAP is adequate, shown by the different median
DAP change scores in the group that reported change in
pain by TRANS-Q and the group that reported no
change, respectively. An improvement of 1.5 or more
DAP points can be interpreted as clinically relevant, re-
lating nicely to previous findings where the minimal
clinically important difference in chronic musculoskel-
etal pain equals a reduction of 15.0 % on the 0–10 NRS
Fig. 1 Numbers of participants enrolled in hosting trial (n = 100),
included in the validity study (n = 93), completing the 6MWTpain
(n = 80) and completing the TRANS-Q (n = 41)
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[21]. However, as the smallest detectable change of the
DAP was previously estimated to be 1.95 for intra-rater
and 2.39 for inter-rater [2], the more conservatively esti-
mated MIC of 2.4 (corresponding to the upper confi-
dence limit of the mean DAP change in the group
experiencing no change) should be used to inform clin-
ical decisions for individual patients.
Ideally, evaluating the construct validity of the DAP
should involve a comparison with a gold standard —
another instrument that is proven to reliably assess pain
during activity. As no such gold standard exists, we fo-
cused on the divergent aspect of construct validity, hy-
pothesizing that the instruments focusing solely on pain
(KOOSpain) or function (KOOSfunction, 6MWT) would
not correlate highly (prespecified as r < 0.7) with the
DAP. Furthermore we added a pain rating to an existing
performance test (6MWTpain), expecting this addition
to reflect a similar construct of pain during activity. A
high correlation (prespecified as r > 0.7) with the
6MWTpain would thus support convergent validity. Al-
though our assumption of divergent validity held true,
the DAP and the 6MWTpain had lower correlations
than expected, not supporting convergent validity. This
finding may be explained by the differences between the
DAP and 6MWTpain. Importantly, the 6MWTpain is
not a standardized instrument and is not designed to
Table 1 Baseline characteristics (n = 93)
N (%) Mean SD Min Q1 Median Q3 Max
Gender, male 36 (38.0)
Age 63.7 8.8 43.9 59.2 64.0 70.0 84.4
BMI 29.1 3.7 19.3 26.1 29.8 31.6 35.0
KL score (0–4, 0 = no OA) 2.8 0.8 1.0 2.0 3.0 3.0 4.0
Ahlback score (0–5, 0 = no OA) 1.0 1.1 0.0 0.0 1.0 1.0 4.0
X-ray, medial compartment most affected 83 (89.0)
DAP (0–10, 0 = best) 3.8 2.2 0.0 2.0 4.0 5.0 9.0
6MWT distance 523 98 153 471 521 585 786
6MWTpain (0–10, 0 = best) 3.4 2.2 0.0 2.0 4.0 4.5 9.0
KOOSfunction (0–100, 100 = best) 62.0 16.3 16.2 50.0 64.7 73.5 94.1
KOOSQoL (0–100, 100 = best) 38.4 13.5 6.2 31.2 37.5 50.0 68.8
KOOSpain (0–100, 100 = best) 54.7 13.6 22.2 47.2 55.6 63.9 83.3
KOOSsport (0–100, 100 = best) 29.2 18.6 0.0 15.0 30.0 40.0 75.0
KOOSsymptoms (0–100, 100 = best) 58.3 17.3 14.3 42.9 60.7 71.4 92.9
BMI body mass index, KL Kellgren Lawrence, DAP dynamic weight-bearing assessment of pain, 6MWT six minutes walking test, 6MWTpain pain score (0–10 NRS)
after 6MWT, Qol quality of life
Table 2 Correlation matrix (construct validity; baseline scores and responsiveness; change scores)
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incorporate a pain score. Further, the activities of knee
bends versus 6 min of walking may not be equally pain
provoking in a population of patients with knee OA.
There are differences in the activities – knee bending
and walking. During the performance of the two tests
there were different responses from the patients; walking
seemed to be more painful in the beginning, but then
fading out, while the pain increased with more knee
bends. This supports that the DAP assess a construct of
weight-bearing activity that is relatively more pain
provoking than 6 min of walking. The DAP is a simple
test with a short duration and a focus on the pain inten-
sity during performance of a specified activity. In the
6MWTpain, the distance walked is the main score,
whereas the pain score can be considered a ‘nice-to-
know’ add-on. Even though the exact construct assessed
by the DAP cannot be described based on these results,
it is suggested that the DAP assess a different construct
than other commonly used instruments, but has the
closest relation to the 6MWpain.
Table 3 Numbers of participants within each TRANS-Q response category and the corresponding DAP change median, range, mean,
SD, and 95 % Confidence limits
DAP change
95 % CI
TRANS-Q (perceived change in pain) n (N = 41) Median Min Max Mean SD Lower Upper
7. A very great deal better 7 −3.0 −4.0 −1.0 −3.0 1.2 −4.9 −1.1
6. A great deal better 6 0.0 −2.0 2.0 −0.2 1.3 −2.4 2.0
5. A good deal better 4 −2.5 −5.0 −2.0 −3.0 1.4 −5.3 −0.7
4. Moderately better 6 −1.5 −8.0 0.0 −2.5 3.1 −7.6 2.6
3. Somewhat better 8 −2.0 −5.0 2.0 −1.9 2.2 −5.5 1.8
2. A little better 6 −0.5 −3.0 1.0 −0.7 1.6 −3.4 2.0
1. Almost the same, hardly any better at all 0
0. The same 4 −0.5 −1.0 2.0 0.0 1.4 −2.3 2.3
−1. Almost the same, hardly any worse at all 0
−2. A little worse 0
−3. Somewhat worse 0
−4. Moderately worse 0
−5. A good deal worse 0
−6. A great deal worse 0
−7. A very great deal worse 0
Improved (7 to 2) 37 −2.0 −8.0 2.0 −1.9 2.1 −5.3 1.6
no change (0) 4 −0.5 −1.0 2.0 0.0 1.4 −2.3 2.3
Table 4 Sensitivity and specificity for DAP change scores, using perceived change in pain as gold standard
DAP changea Sensitivity Specificity 1 - Specificity 1-Sensitivity Sum [1-Sens + 1-Spec]
−9.00 0.000 1.000 0.000 1.000 1.000
−6.50 0.027 1.000 0.000 0.973 0.973
−4.50 0.081 1.000 0.000 0.919 0.919
−3.50 0.216 1.000 0.000 0.784 0.784
−2.50 0.351 1.000 0.000 0.649 0.649
−1.50 0.568 1.000 0.000 0.432 0.432
-.50 0.703 0.500 0.500 0.297 0.797
.50 0.892 0.250 0.750 0.108 0.858
1.50 0.946 0.250 0.750 0.054 0.804
3.00 1.000 0.000 1.000 0.000 1.000
total number of participants who perceived improvement (TRANS-Q score 1–7) = 37
total number of participants who perceived no change (TRANS-Q score 0) = 4
The sum of misclassification is used to determine the most appropriate cutoff score (marked with bold letters).
anegative number indicates a decrease in pain
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The correlation among change scores of the DAP and
the 6MWTpain was low, potentially diluting the DAP
responsiveness either due to poor qualities of the DAP
or inappropriate selection of comparable instruments
(lack of gold standard). However, the correspondence to
patient-reported change in pain (TRANS-Q) may be
seen as an even stronger indicator of actual change than
other instruments show. Thus, we interpret the respon-
siveness of the DAP as adequate.
With a median DAP score of 4 (range 0–9) at baseline,
most of the participants had relatively low pain levels, as
also reflected by the other instruments. Nine participants
reported to have no pain (DAP score 0 at baseline). No
participants experienced worsening of their pain as
assessed by TRANS-Q, and only four participants re-
ported ‘no change’. This cause a limitation to the study, as
only the MIC for improvement can be established, not for
deterioration. Another limitation is constituted from our
choice of anchor. Had the anchor been more specific, e.g.
asking about pain during a weight-bearing activity, or
more general, e.g. asking about wellbeing, the MIC may
have been different. Likewise the TRANS-Q only gives in-
formation about the size of experienced change, not
whether it is important. Thus, the choice of which change
that is considered important was in this case not based on
patient-reports. However, the final MIC of 2.4 is a conser-
vative estimate, in this population corresponding to ‘a
good deal better’ or more, which presumably reflects an
important improvement.
It is a limitation to the DAP that not everyone experi-
ence pain during the test. This may reflect day-to-day
variability of knee pain in patients with knee OA, or that
pain occurs in various situations for the individual
patient (at rest, walking, standing, kneeling etc.). An-
other possible explanation for the low pain level could
be that the study population was eligible for pharmaco-
logical treatment and rehabilitation, thus not very se-
verely affected. On the other hand, all participants did
have both symptomatic and radiographic signs of knee
OA, pointing at advanced knee OA. Including more se-
verely affected patients (e.g., those eligible for surgery)
could influence the results. However, DAP scores of 0 is
not considered a ceiling effect because when there is no
pain, there is no need for further discrimination on this
parameter [3]. The DAP did not show signs of a floor ef-
fect either, as no participants reported ‘worst pain im-
aginable’ (DAP score 10). Whether this absence of floor
and ceiling effects would hold true in a more severely af-
fected population has not been established.
So far, the DAP has been tested by physiotherapists in
a research setting only in a population of people with
knee OA and mild to moderate symptoms, who mostly
benefitted from the exercise intervention in a clinical
trial. Testing beyond these limitations is ongoing.
Conclusions
In conclusion, the DAP possesses divergent validity
compared to currently used instruments for the assess-
ment of knee OA, supporting the potential for this new
way of assessing pain directly during activity. Import-
antly, the DAP change-scores correspond to patient-
reported changes in pain, which proves adequate
responsiveness. A change of 2.4 or more can be inter-
preted as clinically relevant. Hence, the DAP is a prom-
ising alternative to using ‘pain on walking’ as an
inclusion criterion or as a clinical trial outcome.
Abbreviations
6MWT, the 6-min-walk-test; 6MWTpain, the 6-min-walk-test with subsequent
pain rating; BMI, body mass index; COSMIN, the COnsensus-based Standards
for the selection of healthMeasurement INstruments; DAP, the dynamic
weight-bearing assessment of pain; ICC, intraclass correlation coefficient; KL,
Kellgren Lawrence; KOOS, the knee injury and osteoarthritis outcome score;
MIC, minimal important change; NRS, numeric rating scale; OA, osteoarthritis;
OARSI, The Osteoarthritis Research Society International; QoL, quality of life;
ROC, receiver operating characteristic; SDC, smallest detectable change; SEM,
standard error of measurement; TRANS-Q, transition questionnaire
Acknowledgements
We would like to thank the participants in this study. The Parker Institute is
grateful for the support from the Oak Foundation.
Funding
This study was supported by The Oak Foundation, The Danish Physiotherapy
Association, The Danish Rheumatism Association, and Capital Region of
Denmark. Financial support was provided from The Parker Institute. The
sponsors and funders of the study had no role in the study design, data
collection and analysis, interpretation or reporting of this work, or the
decision to submit the work for publication.
Authors’ contributions
LK, EW and MH conceived and designed the study. HB provided patients
and CB, EB and LK acquired the data. LK, RC, EW and MH contributed to the
Fig. 2 Receiver operating characteristic (ROC) curve for the various
cutoff points for DAP change, using perceived change in pain as
gold standard
Klokker et al. Health and Quality of Life Outcomes  (2016) 14:91 Page 7 of 8
analysis and interpretation of data. LK drafted the article, and all co-authors
have commented and approved the final version.
Competing interests
None of the authors have any financial or personal relationships with other
people or organizations that could potentially influence this work or the
conclusions.
Ethics approval and consent to participate
This study was nested within an assessor- and participant-blinded randomized
controlled trial [7]. All participants in this study gave informed consent before
enrolling in the hosting trial. Each participant received a copy of the consent.
Author details
1The Parker Institute, Bispebjerg & Frederiksberg Hospital, Nordre Fasanvej 57,
2000 Frederiksberg, Copenhagen, Denmark. 2The Research Initiative for
Activity studies and Occupational Therapy, Institute of Public Health,
University of Southern Denmark, Odense, Denmark. 3Department of Physical
and Occupational Therapy, Bispebjerg & Frederiksberg Hospital, Copenhagen,
Denmark.
Received: 19 February 2016 Accepted: 10 June 2016
References
1. Klokker L, Osborne R, Waehrens EE, Norgaard O, Bandak E, Bliddal H et al.
The concept of physical limitations in knee osteoarthritis: as viewed by
patients and health professionals. Qual Life Res. 2015;24(10):2423–32.
2. Klokker L, Christensen R, Osborne R, Ginnerup E, Waehrens EE, Bliddal H et al.
Dynamic weight-bearing assessment of pain in knee osteoarthritis:
a reliability and agreement study. Qual Life Res. 2015;24(12):2985–92.
3. de Vet HC, Terwee CB, Mokkink LB, Knol DL. Measurement in Medicine A
Practical Guide. Cambridge, UK: Cambridge University Press; 2011.
4. McAlindon TE, Driban JB, Henrotin Y, Hunter DJ, Jiang GL, Skou ST, et al.
OARSI Clinical Trials Recommendations: Design, conduct, and reporting of
clinical trials for knee osteoarthritis. Osteoarthritis Cartilage. 2015;23:747–60.
5. White SG, McNair P, Laslett M, Hing W. Do patients undergoing physical
testing report pain intensity reliably? Arthritis Care Res (Hoboken).
2015;67:873–9.
6. Cliborne AV, Wainner RS, Rhon DI, Judd CD, Fee TT, Matekel RL, et al.
Clinical hip tests and a functional squat test in patients with knee
osteoarthritis: reliability, prevalence of positive test findings, and short-term
response to hip mobilization. J Orthop Sports Phys Ther. 2004;34:676–85.
7. Henriksen M, Christensen R, Klokker L, Bartholdy C, Bandak E, Ellegaard K,
et al. Evaluation of the benefit of corticosteroid injection before exercise
therapy in patients with osteoarthritis of the knee: a randomized clinical
trial. JAMA Intern Med. 2015;175:923–30.
8. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee Injury and
Osteoarthritis Outcome Score (KOOS)–development of a self-administered
outcome measure. J Orthop Sports Phys Ther. 1998;28:88–96.
9. Collins NJ, Misra D, Felson DT, Crossley KM, Roos EM. Measures of knee
function: International Knee Documentation Committee (IKDC) Subjective
Knee Evaluation Form, Knee Injury and Osteoarthritis Outcome Score
(KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function
Short Form (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale
(KOS-ADL), Lysholm Knee Scoring Scale, Oxford Knee Score (OKS), Western
Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Activity
Rating Scale (ARS), and Tegner Activity Score (TAS). Arthritis Care Res
(Hoboken). 2011;63 Suppl 11:S208–28.
10. Enright PL. The six-minute walk test. Respir Care. 2003;48:783–5.
11. Kennedy DM, Stratford PW, Wessel J, Gollish JD, Penney D. Assessing
stability and change of four performance measures: a longitudinal study
evaluating outcome following total hip and knee arthroplasty. BMC
Musculoskelet Disord. 2005;6:3.
12. Naylor JM, Hayen A, Davidson E, Hackett D, Harris IA, Kamalasena G, et al.
Minimal detectable change for mobility and patient-reported tools in
people with osteoarthritis awaiting arthroplasty. BMC Musculoskelet Disord.
2014;15:235.
13. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP,
et al. Core outcome measures for chronic pain clinical trials: IMMPACT
recommendations. Pain. 2005;113:9–19.
14. van der Roer N, Ostelo RW, Bekkering GE, van Tulder MW, de Vet HC.
Minimal clinically important change for pain intensity, functional status, and
general health status in patients with nonspecific low back pain. Spine
(Phila Pa 1976). 2006;31:578–82.
15. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining
the minimal clinically important difference. Control Clin Trials.
1989;10:407–15.
16. KELLGREN JH, LAWRENCE JS. Radiological assessment of osteo-arthrosis.
Ann Rheum Dis. 1957;16:494–502.
17. Davies AP, Calder DA, Marshall T, Glasgow MM. Plain radiography in the
degenerate knee. A case for change. J Bone Joint Surg Br. 1999;81:632–5.
18. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al.
The COSMIN study reached international consensus on taxonomy,
terminology, and definitions of measurement properties for health-related
patient-reported outcomes. J Clin Epidemiol. 2010;63:737–45.
19. Swinkels RA, Bouter LM, Oostendorp RA, Swinkels-Meewisse IJ, Dijkstra PU,
de Vet HC. Construct validity of instruments measuring impairments in
body structures and function in rheumatic disorders: which constructs are
selected for validation? A systematic review. Clin Exp Rheumatol.
2006;24:93–102.
20. Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences.
5th ed. Boston: Houghton Mifflin; 2003.
21. Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically
important changes in chronic musculoskeletal pain intensity measured on a
numerical rating scale. Eur J Pain. 2004;8:283–91.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Klokker et al. Health and Quality of Life Outcomes  (2016) 14:91 Page 8 of 8
